Congress Squares Off Over Drug Pricing And A Controversial Drug Discount Program
The controversial 340B drug discount program for hospitals came under fire at a congressional hearing.
Drugs
1,121-1,140 of 1,313 results
-
-
REPEAL & REPLACE WATCH
Whichever Way ‘Repeal And Replace’ Blows, Pharma Is Due For Windfall
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
By Emily Kopp -
Amount Of Opioids Prescribed In U.S. Has Been Falling Since 2010
Report by CDC researchers finds a steady fall in opioid use in recent years, but the rates are still three times higher than in 1999.
-
New On The Streets: Drug For Nerve Pain Boosts High For Opioid Abusers
Gabapentin, prescribed for epilepsy and nerve damage, is touted by federal health officials as an alternative to opioids for patients. But some are now abusing the drug.
-
NAVIGATING AGING
Seniors Miss Out On Clinical Trials
Among hurdles: Older adults may have multiple illnesses that could complicate research or they might be unable to manage the commute.
-
Take Our Quiz To Test Your Wits On Aging
As we get older, it helps to tickle the noggin with trivia. Here's a pop quiz to see what you have learned as a regular reader of Kaiser Health News.
-
Patients With Mental Disorders Get Half Of All Opioid Prescriptions
A study finds that nearly 19 percent of people with mental illnesses use prescription drugs, while only 5 percent of other people do.
-
Repeal & Replace Watch
Promises Made To Protect Preexisting Conditions Prove Hollow
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
By Jay Hancock and Rachel Bluth -
Exclusive: White House Task Force Echoes Pharma Proposals
Documents examined by Kaiser Health News shed light on the workings of the Trump administration's “Drug Pricing and Innovation Working Group."
By Emily Kopp -
Tweet Revenge: Twitter Erupts As Diabetes Forum Tries To Lock Down Photo Sharing
This year’s American Diabetes Association scientific meeting came with a hefty price — a policy of no photography and limits on social media. That did not go over well on Twitter.
By Emily Kopp -
‘How Long Have I Got, Doc?’ Why Many Cancer Patients Don’t Have Answers
Due to poor doctor-patient communication, most people with advanced cancer don’t know enough about their disease to make vital decisions.
By Liz Szabo -
Former Pharma Reps’ New Mission: To School Docs On High Drug Costs
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
By Jay Hancock -
Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin Makers’ Profits
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
By Emily Kopp -
When An Insurer Balks And Treatment Stops
A 22-year old man from Orange County, Calif., alleges in a lawsuit that his health insurer stopped paying for a crucial — and expensive — immunotherapy drug, leading him to become seriously ill. Treatments for patients with similar conditions are increasingly denied or interrupted, experts and patient advocates say.
By Anna Gorman -
Many COPD Patients Struggle To Pay For Each Medicinal Breath
One in 9 Medicare enrollees have COPD and many of them can’t afford the inhalers that keep them out of the emergency room.
-
Drug Rebates Reward Industry Players — And Often Hurt Patients
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
-
New York State Wants Its Prescription Drug Money Back — Or Else
A new law gives Medicaid regulators power to threaten drugmakers with cost-effectiveness scrutiny unless they grant additional rebates.
-
Do Best-Selling Drugs That Calm Stomachs Damage Kidneys? The Answer’s Unclear.
With flawed systems for tracking the side effects of prescription drugs, a link between proton pump inhibitors and kidney disease suggested by research cannot be proven. Patients who swear by the drugs hope it won’t be.Â
By Sydney Lupkin and Pauline Bartolone -
Quiz: Help Us Take The Pulse Of Our Readers
Even the most exalted among us realize health care policy is complicated. Here's a pop quiz to see what you have learned as a regular reader of Kaiser Health News.
-
Overwrought Marketing? Ads, Not Research, Create Some Pharma Best-Sellers
A look at how and why strategic, star-studded advertising brought a drug for a little-known neurological condition into your home.